These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8573751)

  • 1. Vascular changes in the diabetic kidney: effects of ACE inhibition.
    Vranes D; Dilley RJ; Cooper ME
    J Diabetes Complications; 1995; 9(4):296-300. PubMed ID: 8573751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies.
    Vranes D; Cooper ME; Dilley RJ
    J Vasc Res; 1995; 32(3):183-9. PubMed ID: 7772678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.
    Allen TJ; Hulthen UL; Rumble JR; Jasik M; Cooper ME
    J Diabetes Complications; 1995; 9(4):318-22. PubMed ID: 8573756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal enlargement and insulin-like growth factor-1 accumulation in the Wistar rat model of experimental diabetes is not prevented by angiotensin converting enzyme inhibition.
    New JP; Canavan JP; Flyvbjerg A; Hamon G; Bilous RW; Marshall SM
    Diabetologia; 1996 Feb; 39(2):166-71. PubMed ID: 8635668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition.
    Cooper ME; Rumble J; Komers R; Du HC; Jandeleit K; Chou ST
    Diabetes; 1994 Oct; 43(10):1221-8. PubMed ID: 7926292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat.
    Rumble JR; Komers R; Cooper ME
    J Hypertens; 1996 May; 14(5):601-7. PubMed ID: 8762203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.
    Davis BJ; Johnston CI; Burrell LM; Burns WC; Kubota E; Cao Z; Cooper ME; Allen TJ
    Diabetologia; 2003 Jul; 46(7):961-71. PubMed ID: 12838387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation of hypotensive effects with prevention of cardiac hypertrophy by perindopril after ligation of rat coronary artery.
    Chiba K; Moriyama S; Ishigai Y; Fukuzawa A; Irie K; Shibano T
    Br J Pharmacol; 1994 Jul; 112(3):837-42. PubMed ID: 7921610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute but not chronic angiotensin-converting enzyme inhibition induces enzyme synthesis in the glomerulus of the spontaneously hypertensive rat.
    Hodge G; Makarious MM; Charlesworth JA; Duggan KA
    Clin Exp Pharmacol Physiol; 1997 Jun; 24(6):460-2. PubMed ID: 9171960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
    O'Brien RC; Cooper ME; Jerums G; Doyle AE
    Diabetes; 1993 Apr; 42(4):604-9. PubMed ID: 8454112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes.
    Erensoy N; Yilmazer S; Oztürk M; Tunçdemir M; Uysal O; Hatemi H
    Acta Histochem; 2004; 106(4):279-87. PubMed ID: 15350810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies.
    Cooper ME; Cao Z; Rumble JR; Jandeleit K; Allen TJ; Gilbert RE
    Metabolism; 1998 Dec; 47(12 Suppl 1):24-7. PubMed ID: 9867067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perindopril treatment in streptozotocin induced diabetic nephropaty.
    Trojacanec J; Zafirov D; Labacevski N; Jakjovski K; Zdravkovski P; Trojacanec P; Petrusevska G
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(1):99-108. PubMed ID: 23928803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
    Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perindopril treatment affects both preglomerular renal vascular lumen dimensions and in vivo responsiveness to vasoconstrictors in spontaneously hypertensive rats.
    Bergström G; Johansson I; Stevenson KM; Kett MM; Anderson WP
    Hypertension; 1998 Apr; 31(4):1007-13. PubMed ID: 9535428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of quinapril and nifedipine on early renal changes in streptozotocin-induced diabetes in rats.
    Petitjean P; Vloemans M; Barthelmebs M; Stephan D; Grima M; Jund A; Imbs JL
    Fundam Clin Pharmacol; 1994; 8(4):356-65. PubMed ID: 7851841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats.
    Black MJ; Kanellakis P; Bobik A
    J Hypertens; 1997 Sep; 15(9):945-54. PubMed ID: 9321741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition.
    Sassy-Prigent C; Heudes D; Jouquey S; Auberval D; Belair MF; Michel O; Hamon G; Bariety J; Bruneval P
    Lab Invest; 1995 Jul; 73(1):64-71. PubMed ID: 7603042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
    Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
    Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.